evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

11 questions · 11 findings · 3 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 9.1%Low 1 · 9.1%Moderate 9 · 81.8%High 0 · 0%

Live zoster vaccine vs placebo

Participants with adverse events: 1 or more serious adverse events regardless of type of storage of the vaccine Clinical or laboratory criteria · healthy older adults aged ≥ 60 years

Live zoster vaccine showed no clear difference in participants with adverse events: 1 or more serious adverse events… compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Participants with adverse events ‐ death Clinical criteria · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ deathClinical criteria compared with placebo (moderate certainty).

1 finding from 1 review

Live zoster vaccine vs placebo

Participants with adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years

Live zoster vaccine probably leads to higher participants with adverse eventsClinical or laboratory criteria compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Participants with adverse events ‐ any local symptom Clinical criteria · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any local symptomClinical criteria compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Adverse effects of any severity (systemic symptoms) · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any systemic symptomClinical… compared with placebo (moderate certainty).

1 finding from 1 review

Live zoster vaccine vs placebo

Participants with adverse events ‐ injection site adverse events Clinical criteria · healthy older adults aged ≥ 60 years

Live zoster vaccine probably leads to higher participants with adverse events ‐ injection site adverse… compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Participants with adverse events ‐ serious adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ serious adverse eventsClinical or… compared with placebo (moderate certainty).

1 finding from 1 review

Live zoster vaccine vs placebo

Systemic adverse events at · healthy older adults aged ≥ 60 years

Live zoster vaccine showed no clear difference in participants with adverse events ‐ systemic adverse eventsClinical… compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Participants with adverse events ‐ potential immune‐mediated disease Clinical or laboratory criteria · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ potential immune‐mediated… compared with placebo (moderate certainty).

1 finding from 1 review

Loratadine 10 mg vs placebo (4‐week intervention)

Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema

Loratadine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).

1 finding from 1 review